# Kevin Slawin

> Kevin Slawin is a Series A investor at Ponce Therapeutics backing Health Care and Therapeutics. See 3 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Ponce Therapeutics](https://shizune.co/investors/profile/ponce-therapeutics)
- Location: Miami Beach, United States
- Total investments: 3
- Last investment: Apr 2021
- Lead investor: 33%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/kevinslawin
- X (Twitter): https://twitter.com/kevinslawinmd
- Website: https://x.com/kevinslawinmd
- Facebook: https://www.facebook.com/kevin.slawin

Kevin Slawin is a Series A investor at Ponce Therapeutics in Miami Beach focused on Health Care and Therapeutics. Kevin M. Slawin is based out of Miami Beach, Florida, and is the Founder, CEO, and Chairman of Ponce Aurora. Kevin Previously worked at Memorial Hermann Health System as a Director of Urology - MMH TMC. Kevin M. Slawin attended Columbia University. Kevin M. Slawin has been awarded the F. Brantley Scott, Jr. Award for Innovation and Creativity inUrology.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 2 | 67% |
| Therapeutics | 1 | 33% |
| Biotechnology | 1 | 33% |
| Medical Device | 1 | 33% |
| Health Diagnostics | 1 | 33% |

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 2 | 67% |
| Convertible Note | 1 | 33% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| Israel | 1 | 33% |
| United States | 1 | 33% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| FIZE Medical | Fize Medical offers novel tools for reliable, monitoring of patient, its initial solution is a way to track renal output continuously. | $5.3M | Series A | Apr 06, 2021 |  |
| AsclepiX Therapeutics | AsclepiX Therapeutics represents the next generation of biologics and drug development technology. They use bioinformatics and systems biology methods to design classes of short biomimetic anti-angiogenic (anti-neovascular), and anti-lymphangiogenic peptides. They also use the latest developments in biomaterials and drug delivery to designlong-lasting biodegradable nano and microparticles to deliver these biomimetic therapeutic peptides throughout the body.AsclepiX Therapeutics utilizes its platform technology for indications in ophthalmology, oncology, and for other angiogenesis and lymphangiogenesis-dependent diseases. | $35M | Series A | Jun 24, 2020 |  |
| AsclepiX Therapeutics | AsclepiX Therapeutics represents the next generation of biologics and drug development technology. They use bioinformatics and systems biology methods to design classes of short biomimetic anti-angiogenic (anti-neovascular), and anti-lymphangiogenic peptides. They also use the latest developments in biomaterials and drug delivery to designlong-lasting biodegradable nano and microparticles to deliver these biomimetic therapeutic peptides throughout the body.AsclepiX Therapeutics utilizes its platform technology for indications in ophthalmology, oncology, and for other angiogenesis and lymphangiogenesis-dependent diseases. | $5M | Convertible Note | Nov 13, 2018 |  |

3 of 3 investments shown.

## Co-investors
- [Barer & Son Capital](https://shizune.co/investors/profile/barer-son-capital) — VC Fund, 2 deals together
- [TEDCO](https://shizune.co/investors/profile/maryland-technology-development-corporation) — VC Fund, 1 deal together
- [Mendham Investment Group](https://shizune.co/investors/profile/mendham-investment-group) — VC Fund, 1 deal together
- [Perceptive Advisors](https://shizune.co/investors/profile/perceptive-advisors) — VC Fund, 1 deal together
- [Piedmont Capital Partners](https://shizune.co/investors/profile/piedmont-capital-partners) — VC Fund, 1 deal together
- [Salem Partners](https://shizune.co/investors/profile/salem-partners) — VC Fund, 1 deal together

## About Ponce Therapeutics

VC Fund



2 contacts available at Ponce Therapeutics.

| Name | Title | Profile |
| --- | --- | --- |
| Kevin Slawin | Founder, President & CEO | https://shizune.co/investors/profile/kevin-slawin |
| Kevin Slawin | Founder, President & CEO | https://shizune.co/investors/profile/kevin-slawin-ffa0 |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Kevin Slawin invest in?

Kevin Slawin invests primarily in Health Care, Therapeutics and Biotechnology startups, most often at Series A and Convertible Note stage. Most of the 3 investments tracked by Shizune back companies in Israel. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Kevin Slawin last invest?

The most recent investment recorded for Kevin Slawin closed in Apr 2021. Shizune tracks 3 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co